While breast cancer is not a robustly immunogenic tumor type overall, certain subtypes, largely the estrogen receptor-negative tumors, have more abundant immune cell infiltration, representing opportunities for immune checkpoint inhibitors. This evidence concerns the gene ESR1 and breast carcinoma.